The Journal of Allergy and Clinical Immunology
Volume 113, Issue 1 , Pages 115-119 , January 2004

Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes

  • Jennifer K Garrett, PA-C

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Sean C Jameson, BA

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Blythe Thomson, MD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Margaret H Collins, MD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Lynne E Wagoner, MD

      Affiliations

    • Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    • ,
  • Debbie K Freese, MD

      Affiliations

    • Department of Pediatrics, Mayo Clinic and Foundation, Rochester, Minn, USA
    • ,
  • Lisa A Beck, MD

      Affiliations

    • Department of Medicine, Johns Hopkins Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Md, USA
    • ,
  • Joshua A Boyce, MD

      Affiliations

    • Department of Medicine, Brigham and Women's Hospital, Department of Pediatrics, Massachusetts General Hospital, Boston, Mass, USA
    • ,
  • Alexandra H Filipovich, MD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Joyce M Villanueva, BS

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Steven A Sutton, MD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Amal H Assa'ad, MD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • ,
  • Marc E Rothenberg, MD, PhD

      Affiliations

    • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
    • Corresponding Author InformationReprint requests: Dr Marc E. Rothenberg, Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7028, Cincinnati, OH 45229

Received 11 October 2003 ,Revised 20 October 2003 ,Accepted 12 December 2003.

  • Image Result

    Effect of anti–IL-5 on eosinophil blood counts. Peripheral blood eosinophil counts in patient 2 (A) and patient 3 (B) are shown. Arrows indicate points of intervention with anti–IL-5 therapy.

    Effect of anti–IL-5 on eosinophil blood counts. Peripheral blood eosinophil counts in patient 2 (A) and patient 3 (B) are shown. Arrows indicate points of intervention with anti–IL-5 therapy.

  • Image Result

    Histologic analysis of esophageal biopsy specimens before and after anti–IL-5. Representative sections from esophageal biopsies taken before (A) and after (B) anti–IL-5 were stained with hematoxylin a

    Histologic analysis of esophageal biopsy specimens before and after anti–IL-5. Representative sections from esophageal biopsies taken before (A) and after (B) anti–IL-5 were stained with hematoxylin and eosin. A, Biopsy specimen from the proximal esophagus shows numerous eosinophils throughout the epithelium, including at the luminal surface. Representative eosinophils are indicated with arrows. B, Only scattered intraepithelial eosinophils are present. Original magnification ×200.

  • Image Result
    Effect of anti–IL-5 on esophageal eosinophil counts. Values are mean ± SD of the number of eosinophils in all HPF per specimen at time of diagnosis, before (week 8) and after (week 20) anti–IL-5. Ther

    Effect of anti–IL-5 on esophageal eosinophil counts. Values are mean ± SD of the number of eosinophils in all HPF per specimen at time of diagnosis, before (week 8) and after (week 20) anti–IL-5. There was a statistically significant difference in eosinophil levels between post–anti–IL-5 and time of diagnosis (P < .01) and week 8 (P < .01) values as determined by Student t test.

☆ Supported in part by the Burroughs Wellcome Fund and the NIH-supported Clinical Research Center and the Translational Research Office at Cincinnati Children's Hospital Medical Center.

PII: S0091-6749(03)02533-8

doi: 10.1016/j.jaci.2003.10.049

The Journal of Allergy and Clinical Immunology
Volume 113, Issue 1 , Pages 115-119 , January 2004

Article Tools

* Image Usage & Resolution